

GENOME THERAPEUTICS CORP

Form 8-K

February 02, 2004

---

# SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

---

## FORM 8-K

CURRENT REPORT

Pursuant to

Section 13 or 15(d) of

THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of Earliest Event Reported): February 2, 2004

---

# GENOME THERAPEUTICS CORP.

(Exact name of registrant as specified in its charter)

Massachusetts  
(State or other jurisdiction of incorporation)

0-10824  
(Commission File Number)

04-2297484  
(I.R.S. Employer Identification Number)

100 Beaver Street

Waltham, Massachusetts 02453

(Address of principal executive offices, including zip code)

(781) 398-2300

(Registrant's telephone number, including area code)

---

Page 1 of 4 pages.

**ITEM 5. OTHER EVENTS**

On January 31, 2004, Genome Therapeutics Corp. issued a press release announcing Nasdaq's interpretation regarding Genome's registered common stock offering, which is attached hereto as Exhibit 99.1.

**Item 7. FINANCIAL STATEMENTS AND EXHIBITS.**

(c) Exhibits

99.1 Press Release issued by Genome Therapeutics Corp. on January 31, 2004.



**EXHIBIT INDEX**

<b>Exhibit Number</b>	<b>Description</b>
99.1	Press Release issued by Genome Therapeutics Corp. on January 31, 2004.